Oxurion NV operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oxurion NV with three other
miscellaneous service companies in Europe:
GW Pharmaceuticals PLC
of the United Kingdom
sales of £8.24 million [US$10.34 million]
of which 94%
(9.86 million Euro [US$11.12 million]
Midatech Pharma PLC
based in the United Kingdom
(£7.60 million [US$9.53 million]
of which 88%
During the year ended December of 2017, sales at
Oxurion NV were 9.06 million Euro (US$10.21 million).
increase of 27.5%
versus 2016, when the company's sales were 7.10 million Euro.
Despite this increase, sales are still
below the level achieved in 2015, when Oxurion NV
reported sales of 11.20 million Euro.